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Poster Session-I 79serotherapy alone, 6 pts with reduced intensity regimens, and 3
pts received no conditioning. Median age at the second SCT
was 6.2 years (range, 0.3–14.2 years) and the median time from
the first SCT to the second SCT was 10.3 months (range, 1.2–
84 months).
Results: 40 patients had initial engraftment, median time to ANC
$ 500  106/l was 19 days (range, 9–28 days), and median time to
a platelet count $ 20  109/l was 26.5 days (range, 10–100 days).
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD
of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and
event free survival (EFS) were 66% and 50% respectively. When sur-
vival was evaluated by the interval between the 1st and 2nd SCT:\6
months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55%
and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year
EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005).
With intervals of\ 12 months (26 pts) and $ 12 months (25 pts),
the 10-year OS was 64% and 70% for the 2 cohorts respectively
(P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts
respectively (P 5 0.2). When survival was evaluated by underlying
disease, the 10-year OS was 59%, 75% and 59% for pts
with NMHD, IMD and leukemia respectively (P 5 0.3), and the
10-year EFS was 55%, 50%, and 59% (P5 0.5) for the same groups
respectively.
Conclusions: Second SCT in children is relatively well tolerated
and is associated with reasonable survival. OS and EFS appear to be
considerably better when the interval between the 2 transplants is$
6 months.214
RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PA-
TIENTS WITH LEUKOCYTE ADHESION DEFICIENCY TYPE I
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Objective: Hematopoietic stem cell transplantation (HSCT) is
the only curative treatment of some congenital immunodefi-
ciency diseases especially leukocyte adhesion deficiency type-I
(LAD-I).
Methods: Six patients (3 girls, 3 boys), received allogeneic HSCT
between 2007 and 2008. One patient received stem cell from her
healthy full human leukocyte antigen (HLA) matched sibling, three
patients from their full matched other related (one from father, one
from mother and one from uncle which verified with high resolution
HLA matching method), one patient from his mother (haploidenti-
cal) and one patient from his father with one antigen mismatch. The
graft source was bone marrow in 4 patients and peripheral blood
stem cells (PBSC) in others. Median age at HSCT was 17 months
(10.2–87.8 months). All patients were conditioned with Fludarabine,
Melfalan and Antithymocyte globulin (ATG). For graft-versus-host
disease (GVHD) prophylaxis, we used Cyclosporine and Methyl-
prednisolone.
Results: All patients engrafted. Median time of Absolute Neutro-
phil Count $ 0.5109 /L was 113 and median time of Platelet re-
covery $20109 /L was 116. Median follow-up of patients was 8
months (range, 1–20 months) and at present five (83%) patients
are alive with sustained engraftment and without recurrent infection
and improvement of their failure to trive. Three patients developed
acute GVHD after transplantation that one of them died because of
acute GVHD one month after transplantation. No chronic GVHD
occurred. Full chimerism was achieved in one patient and mixed chi-
merism was achieved in four patients.
Conclusions: Early diagnosis and HSCT of LAD-I rescue
patients from lethal disease but not all of patients have full match
siblings and others must transplanted from other related, haploi-
dentical relative, non relative full match or cord blood. Analysis
of our patients who developed mixed chimerism suggested that
this mixed chimeric state resulted in a reversal of the LAD-I
phenotype.215
STABLE MIXED CHIMERISM AFTER NON-MYELOABLATIVE TRANSPLANT
FOR SICKLE CELL DISEASE: NORMAL HEMATOPOIESIS DOMINATES OVER
ABNORMAL IN MIXED CHIMERISM
Ildstad, S.1, Cheerva, A.2, Tollerud, D.1, Bertolone, S.2, Herzig, G.2,
Herzig, R.2 1University of Louisville, Louisville, KY; 2University of
Louisville, Louisville, KY
Allosensitization due to transfusion therapy has been a barrier to
engraftment in patients with sickle cell (SC) disease, requiring the
use of more intense conditioning. In a mouse model, sensitization
to bone marrow cells (BMC) results predominantly from the hu-
moral immune response. We added alemtuzumab (anti-CD52) lym-
phodepletion for conditioning recipients for a hematopoietic cell
transplant. 2 cycles of alemtuzumab were administered with the ra-
tionale of eliminating memory B cells by inducing them to undergo
homeostatic proliferation after the 1st round of depletion. Condi-
tioning consisted of alemtuzumab (10 mg/day, days -53— -50 and
days -24 —-21), fludarabine (30 mg/m2/day days -5 —-3), 200 cGy
TBI (day -1), matched related donor BM infusion day 0, followed
by cyclosporine and mycophenolate mofetil (day-1—.10 months).
2 patients have been transplanted. Patient 1 was 7 at transplant,
with a history of multiple pain crises, episodes of acute chest syn-
drome, and extensively treated with exchange transfusion therapy
and hydroxyurea. She received 14.5  106kg CD34 cells from her
HLA-identical sibling donor with SC trait, showing 78% donor en-
graftment day 30. Her RBC production remained phenotypically
trait which is compatible with donor hematopoiesis . 615 days
post-transplant, with donor lymphoid and myeloid chimerism con-
sistently 20–30%. Immunosuppression was discontinued 10 months
post-stem cell transplantation (SCT). Patient 2 was 9 at transplant
with multiple pain crises, 2 episodes of acute chest syndrome before
transplant, and had been treated with exchange transfusions for 7
years. He received HLA-matched sibling donor BM, processed to
deplete T- and B cells. The graft contained 5.24  106/kg CD34,
0.55  106/kg ab-TCR and 0.35  106/kg FC cells. He has been
transfusion-independent post-SCT, with 100% donor RBC produc-
tion and chimerism levels at 20–30% donor by FISH .851 days
post-transplant. Immunosuppression was discontinued at 23 months
post-SCT. Neither patient had GVHD, transplant-related toxicity,
or SC complications since transplant. Data suggest that the addition
of an alemtuzumab split-course to a nonmyeloablative transplant
regimen allows hematopoietic cell engraftment of allosensitized re-
cipients with SCD without GVHD. Stable mixed chimerism of my-
eloid and lymphoid lineages is accompanied by full donor
erythropoiesis. Stable mixed chimerism may also have been achieved
due to prolonged post-SCT immunosuppression from MMF.216
BONE MINERAL DENSITY, LEAN BODY MASS, CALCIUM AND VITAMIN D
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Introduction: Hematopoietic stem cell transplantation (HSCT)
has been associated with decreased food intake, malnutrition, re-
duced lean body mass and reduced bone mineral density (BMD),
which might result in increased morbidity and mortality. The pur-
pose of this study was to evaluate the BMD, lean body mass, calcium
and vitamin D intake in children and adolescents before and 6
months after HCT.
Patients andMethods:Forty patients (25 boys and 15 girls; mean
age: 10,16 4,26 yrs) who were consecutively submitted to allogenic
HSCT between September 2006 and March 2008 and survived after
6 months were included in the analysis. BMD was evaluated by DXA
(HOLOGIC-1000) at the lumbar spine (LS) and whole body (WB),
lean body mass by bioelectrical impedance analysis and food intake
by a 24 hours recall and food frequency questionnaire.
Results: LS BMD was 0,6736 0,167 g/cm2 in the first evaluation
and 0,6626 0,78 g/cm2 in the second evaluation (p. 0.05). The WB
BMD was 0,850 6 0,164g/cm2 in the first evaluation, reducing to
80 Poster Session-I0,833 6 0,155 g/cm2 in the second evaluation (p\0,01). The mean
reduction of the BMD was -1.7 6 9.2% in the LS and -1.7 6
3.3% in the WB. Fourteen (35%) patients had a reduction greater
than 5% in LS, 9 (64%) of them were submitted to unrelated allo-
genic HCT, and 10 (71%) developed Graft Versus Host Disease
(GVHD). Nine patients (13%) had a reduction greater than 5% in
lean body mass. Fifteen patients (38%) had insufficient calcium in-
take in the first evaluation and 20 patients (50%) in the second eval-
uation. Seven patients (18%) had insufficient vitamin D intake in the
first evaluation and 12 patients (30%) in the second evaluation. We
found a positive correlation between changes in BMD in the whole
body and changes in body weight (r 5 0,38; p\0,01).
Conclusion: The prevalence of BMD and lean body mass reduc-
tion was high after six months of HSCT. There was an important de-
crease in the calcium and vitamin D intake. Children and adolescents
undergoing HCT need nutritional intervention and we suggest
a routine BMD evaluation in those who are at risk for reduction in
bone mass.217
A POPULATION-BASED SINGLE INSTITUTION EVALUATION OF 16 YEARS
OF ALLOGENEIC HSCT IN CHILDHOOD ALL
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ALL remains one of the most important causes of haematopoietic
stem cell transplantation (HSCT) in children. The outcome of the
procedure depends on several factors e.g.: 1) ALL subtype 2) pre
transplant treatment 3) leukaemia stage at transplantation 4) condi-
tioning regimen and GvH prophylaxis 5) donor selection and 6)
quality of supportive treatment. In a retrospective analysis of popu-
lation-based data prospectively collected we made an attempt to an-
alyse these factors in a Danish context.
Patients:The course of 85 children\18 years diagnosed between
1–1 1992 and Oct 2008 was examined. This cohort constituted all
children with ALL transplanted in Denmark in this period. All pa-
tients were transplanted at the same centre. Forty-five patients re-
ceived first line treatment according to the Nordic NOPHO1992
protocol and 40 patients according to the NOPHO2000 protocol.
Results: A significant improved survival was recorded between
patients pre-treated according to the NOPHO1992 (KM 5y sur-
vival: 51%) and the later NOPHO2000 protocol (KM 5y survival:
70%). Since the overall survival results for the two treatment pro-
tocols are essentially the same the difference in transplant outcome
is supposed to be due to transplant related causes. An analysis of the
causes for this difference showed that predominantly TRM has de-
clined in the later period but the risk for relapse also decreased. The
survival chance of children transplanted with an HLA-id Sib donor
was particularly good with a KM 5y-survival of around 80%.
The survival of patients transplanted with an UD had a KM 5y-
survival of around 60%. Among factors that were found to be
important for the improved survival were the inclusion of etoposide
in the conditioning regimen and the exclusion of MTX for GvH
prophylaxis.
Conclusion: Significant improvement in survival of ALL children
after HSCT has occurred within the past 16 years. It is presumed that
during recent years patients in need of an HSCT are not in a better
general condition than earlier and do not have a less aggressive dis-
ease. Never the less as well an improvement in TRM as in the risk of
relapse explain the overall improvement in survival.218
REDUCTION OF TREATMENT RELATED MORTALITY AFTER STEM CELL
TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH ALL UN-
DERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: THE VALUE
OF SEVERE ADVERSE EVENT REPORTING
Schrauder, A.1, Schrappe, M.1, Stackelberg, A.2, Bader, P.3, Peters, C.4
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Vienna, AustriaAlthough allogeneic stem cell transplantation (alloSCT) effec-
tively prevents relapse of acute lymphoblastic leukemia (ALL), trans-
plant related mortality (TRM) may counterbalance that beneficial
effect. In 2003 the BFM Study Group initiated a prospective interna-
tional multicenter trial. aiming to standardize and harmonize the
SCT procedure in order to minimize risk of TRM. The immediate
reporting of severe adverse events (SAE) is mandatory in this ongo-
ing study and the findings are regularly discussed within study com-
mittee meetings. Here we report on the frequency, incidence and
outcome of SAE’s in study protocol patients who underwent al-
loSCT between September 2003 and June 2008. 262 children and
adolescents with ALL were recruited by 27 participating SCT cen-
ters. Indications for SCT were all high risk leukemia in any remis-
sion. Conditioning regimen was TBI1VP16 for SCT from MSD
(matched sibling donor), TBI1VP161ATG for SCT from MD
(matched donor), and TBI1Flu1VP161ATG for SCT from
MMD (mismatched donor).
Results: Ninetyone forms reported on life threatening, fatal or
unanticipated problems. Most common reported events were acute
respiratory distress syndromes, disseminated viral infections , bac-
terial sepsis and acute GVHD grade III and IV. Veno-occlusive
disease and other life threatening toxicities were rare events.The
day 360-TRM was 5% in the MSD-group, 4% in the MD-group
and 25% in the MMD group. Overall, 25/262 pts died due to treat-
ment related events. Five pts died after MSD-SCT (all had
a MMD-indication): 2 pts experienced multi organ failure (MOF)
due to infections, 2 pts due to severe acute GVHD and 1 pt
because of extensive chronic GVHD. In the MD-group (all were
transplanted from unrelated donors) 11 pts had fatal treatment
associated outcome: 8 infection associated MOF, 1 EBV-
lymphoproliferative disease, 2 cerebral complications of unidenti-
fied origin, 1 severe bleeding). Four/11 pts underwent second SCT
due to primary or secondary graft failure. Six pts died after
MMD-SCT: 2 after a second or third transplant procedure due
to graft failure, all of them were infection-associated (5 viral, 1
Listeria-meningitis). We conclude that the high quality perfor-
mance of participating centers as well as excellent compliance to
the recommended regimen, better diagnostic measures and
(pre-emptive) treatment of infections, and close and prospective
monitoring of all patients may contribute to the reduced TRM
after alloSCT in children with ALL.219
PREVALENCE, RISK FACTORS AND MANAGEMENT OF METABOLIC SYN-
DROME AFTER STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS
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Background: Metabolic syndrome (MS) is reported to be highly
prevalent in survivors of cancer and allogeneic stem cell transplant
(SCT). TBI, chemotherapy, GVHD and it’s treatment have been
implicated as factors leading to MS after allogeneic SCT.We report
preliminary results of the study which is being done with the objec-
tives 1) to estimate the prevalence of MS in children followed at a sin-
gle US institution; 2) to analyze risk factors associated with the
development of MS; and 3) to correlate MS with other endocrine dis-
orders post-SCT.
Methods: All patients in the follow-up clinic (.1 year post-SCT)
are screened for lipid profile, BP, BMI, waste-hip ratio, microalbu-
minuria. Diagnosis of MS is based on NCEP-ATPIII criteria.
Once diagnosed, patients are retrospectively analyzed regarding de-
mographics, type of SCT, pre-transplant BMI, occurrence and treat-
ment of GVHD, associated endocrine issues. Patients are educated ,
placed on statins and liver function monitored periodically.
Results: 32 patients have been screened till date and 11 (34.3%)
diagnosed with MS. The median age is 15 years (11–20 years); 6 fe-
male and 5 male. The median duration from SCT to diagnosis was
7.5 years (2.5–14.7 yrs). 7 patients received an allogeneic and 4 an au-
tologous SCT with varied preparative regimens. The median BMI at
the time of diagnosis was 22.74 (20.5–36.6). Only 3 (27%) patients
were overweight (BMI. 25) at the time of SCT; there was an aver-
age BMI increase of 5.5 (0.98–9.4) in the interim between SCT and
diagnosis. Hypertriglyceridemia and hypertension were the most
